Baidu Sold the Top of the Page to a Hospital. A Dying Student Found It There.
In 2016 a 21-year-old cancer patient died after a paid Baidu result led him to an unproven therapy that cost his family over 200,000 yuan. The regulators acted in days - and what they produced was an ad-labeling rule, not accountability.
Comes with a free Crisis Response Playbook template.
A 21-year-old computer-science student at Xidian University typed his own diagnosis into a search box: synovial sarcoma, a rare and aggressive soft-tissue cancer. Near the top of the first page of Baidu results, his family found a treatment center at the Second Hospital of the Beijing Armed Police Corps, offering a cell therapy that promised time he didn't have. They spent more than 200,000 yuan - over $31,000 - on it. Wei Zexi died on April 12, 2016.1 He had already written his own verdict. In February, before he died, he posted a long account on Zhihu condemning the pay-for-placement results that led him there; after his death it drew over 44,000 endorsements and spread across Weibo.6
The official story became a story about a bad advertiser - a rogue clinic that slipped through Baidu's checks, a tragedy of one fraud. That framing is comforting and it is wrong. Wei Zexi was not a glitch in Baidu's system. He was the system working exactly as designed: a desperate medical query, monetized at the moment of maximum desperation, sold to the highest bidder and dressed up to look like an answer.
The product wasn't search. It was the patient.
Here is the mechanism, worked all the way down. Baidu's medical-search business didn't sell ads next to the answer - it sold the answer's position. The center Wei's family trusted wasn't even part of the hospital; it had been subcontracted out to a private company in violation of regulations, and was suspended within days of the scandal breaking.5 The treatment, DC-CIK immunotherapy, was classified in China as a category-three medical technology requiring Health Ministry approval for clinical use - approval it never had. The ministry's probe later uncovered illegal subcontracting of the therapy to a private firm and unauthorized deployment of the technology.8 Strip the institutional camouflage away and what remains is a chain of intermediaries, each taking a cut: a military hospital renting out its name, a private firm running an unapproved therapy, and a search engine selling the top of the page to whoever bid most. The patient was the only one in the chain who paid in something other than money.
And the camouflage was deliberate at the interface, too. The hospital's listing was technically labeled as a promotion - but the label was two small gray characters, easily lost in a page that otherwise looked like organic results. Google, by contrast, used color labels to flag paid placements. Wei's parents said the hospital appeared second from the top on the first page.4 When you make a paid result indistinguishable from an objective one, you are not selling advertising. You are selling the appearance of being unbought - which is the one thing a paid result can never honestly be.
“The labels were two small gray characters, not clearly distinguished from organic results - unlike Google, which used color labels.”4
This had happened before - twice that anyone bothered to count
If Wei Zexi were an accident, you would expect it to be the first of its kind. It wasn't. As far back as November 2008, CCTV reported that Baidu sold priority placement for medical terms to fake hospitals and unlicensed medicine suppliers. In January 2016 - months before Wei's death - Baidu was found selling moderation rights for illness-related Tieba forums to private hospitals, effectively handing control of patient communities to the people selling to them.7 A single fraud is a failure of vetting. A decade of the same fraud, repeated at every layer of the medical funnel, is a business model. The scandal wasn't that Baidu got fooled. It was that the most profitable thing Baidu could do with a sick person's search was the thing it kept doing.
| The 'rogue advertiser' story | The structural reality | |
|---|---|---|
| The cause | One bad clinic slipped through | Pay-for-placement on medical queries, by design |
| The hospital | A trusted military hospital | Its name rented to a subcontracted private firm |
| The therapy | Experimental but plausible | Category-three tech with no required approval |
| The pattern | First time it happened | Documented as far back as 2008 |
| Who paid | An unlucky family | The only party in the chain without a cut |
The state moved in days. What it built was a label.
The government's response was fast in optics. On May 2, 2016, the Cyberspace Administration of China announced it would investigate Baidu's role in the death.2 The investigation concluded what Wei's Zhihu post had already said: that Baidu's pay-for-placement results compromised the fairness and objectivity of search. Regulators ordered Baidu to attach eye-catching markers and disclaimers to ads, and to cap promoted results at 30% of the page.2 On June 25, the CAC issued nationwide rules - effective August 1 - requiring search providers to mark paid results item by item, examine advertiser qualifications, and cap paid content per page, with the new regime explicitly triggered by Wei's death.3
Read those remedies carefully and notice what they fix and what they don't. Every measure is about labeling and proportion - making the paid result more obvious, making there be fewer of them. None touches the underlying incentive: that life-or-death medical queries remain auctionable at all. A clearer label on a slot that should not exist is a cosmetic answer to a structural problem. The state addressed the gray characters, not the auction behind them. And the other culpable parties - the military hospital that rented its name, the regulatory gap that let an unapproved therapy reach a paying patient - largely escaped the headline accountability that fell on Baidu's stock and reputation.
Wasn't this really a healthcare failure, not a Baidu one?
The honest counter is strong, and it deserves to be stated at full strength. Baidu didn't run the clinic, didn't perform the therapy, didn't classify DC-CIK as category-three and then fail to enforce that classification. A desperate family in a healthcare system with thin trust and patchy oversight would have sought unproven cures with or without a search engine; the hospital and the Health Ministry carry real blame, and the academic record agrees the rot ran through the medical system itself.8 Pin everything on Baidu and you let the genuinely dangerous failure - a military hospital subcontracting an unapproved therapy to a private firm - quietly off the hook.5
All true. But it answers a question nobody is really asking. The charge against Baidu was never that it caused the cancer or invented the fraud. It was that it stood at the exact chokepoint where a frightened person decides whom to trust, and it sold that decision - knowingly, repeatedly, since at least 2008.7 A toll-taker doesn't escape responsibility by pointing out it didn't build the cargo. The healthcare system supplied the fraud; Baidu supplied the credibility, and the credibility was the part that converted. The two failures aren't rivals for blame. They're the same failure, met in the middle of a search results page.
A search engine, a ratings agency, a review platform, a pharmacy counter - any business that profits from being believed is selling the same scarce asset: the user's assumption that the answer wasn't bought. Monetize that assumption directly and you get a beautiful margin for exactly as long as nobody notices. The danger isn't a single bad actor slipping through; it's that the most profitable use of the trust is to quietly auction it, so the incentive keeps pulling you toward the edge no matter how good your intentions. Two cautions. First, the failure is structural, not anecdotal - so a fix that only relabels the symptom (a clearer 'sponsored' tag) leaves the incentive untouched and the next crisis fully funded. Second, trust spends down faster than it builds: it took Baidu years to build the habit of being the place China searched, and a single 21-year-old's death to make that habit feel dangerous. Audit where your revenue and your credibility point in opposite directions - and assume your users eventually will too.
The market did its own accounting in the days after the story went viral, knocking Baidu's stock down sharply as the investigation was announced. But the durable cost wasn't in the share price, which recovers. It was that hundreds of thousands of people who had typed their fears into Baidu's box now understood what the answer at the top of the page might be worth to the person who put it there. The regulators gave Baidu a label to apply and a percentage to obey. What they could not legislate back into existence was the thing Wei Zexi's post took away: the quiet, unthinking belief that the first thing you find when you're dying is the truest. That was always Baidu's real inventory. It spent it one search at a time, and discovered - the way these things are always discovered, too late - that you only get to sell it once.
When the business model is the scandal
Crisis Response Playbook
A playbook for a crisis already in motion: who decides, which plays fire on which trigger, and what gets said to whom. It replaces panic and the all-hands meeting with a pre-agreed sequence each person can run alone. Blank to pre-load before a crisis hits; filled as the worked example reconstructing the plays the story's team ran — and the ones they should have.
The worked example unlocks with a subscription. See plans →
Sources
Where this comes from — the filings, records, and reporting behind it.
- 1Wei Zexi was a 21-year-old computer science student at Xidian University in Shaanxi who died on April 12, 2016 from synovial sarcoma after undergoing DC-CIK immunotherapy he found via a paid Baidu search result at the Second Hospital of the Beijing Armed Police Corps, spending over 200,000 yuan (approx. $31,000 USD) on the treatments.
- 2On May 2, 2016, the Cyberspace Administration of China announced it would investigate Baidu's role in Wei's death; the investigation concluded that Baidu's pay-for-placement results influenced the fairness and objectivity of search results; regulators ordered Baidu to attach eye-catching markers and disclaimers to advertisements and reduce promoted results to 30% of the page.
- 3On June 25, 2016, China's CAC issued the Administrative Provisions on Internet Information Search Services, effective August 1, 2016, requiring search service providers to mark paid results item by item, examine advertiser qualifications, and cap paid content per webpage — directly triggered by Wei's death.
- 4The hospital's paid listing result was labeled as a promotion but the labels were two small gray characters — not clearly distinguished from organic results — unlike Google which uses color labels; Wei's parents stated the hospital appeared second from the top on Baidu's first page of results.
- 5The biotherapy center at the Second Hospital of the Beijing Armed Police Corps was not part of the hospital itself but was subcontracted to a private company in violation of regulations; the center's operations were suspended by May 2, 2016.
- 6Wei posted a long article on Zhihu in February 2016 (before his April 12 death) condemning Baidu's pay-for-placement practices; the post went viral after his death, garnering over 44,000 agrees and hundreds of thousands of Weibo views. The hospital's alleged collaboration with Stanford University was later reported by state media to be false.
- 7The Wei Zexi scandal was not Baidu's first medical advertising controversy: CCTV reported in November 2008 that Baidu sold priority placement for medical terms to fake hospitals and unlicensed medicine suppliers; in January 2016, Baidu was found selling moderation rights for illness-related Tieba forums to private hospitals.
- 8DC-CIK therapy was classified as a category-three medical technology in China requiring Health Ministry approval for clinical application, which it lacked; the Health Ministry's probe uncovered illegal subcontracting of the therapy to private firm Shanghai Claison Healthcare and unauthorized deployment of the technology.